Israeli medtech SME developing a catheter-delivered embolic protection device to prevent stroke during transcatheter aortic valve replacement (TAVI).
Filterlex Medical develops and commercializes embolic protection devices (EPDs) designed to prevent stroke during transcatheter aortic valve implantation (TAVI) procedures — a minimally invasive heart valve replacement technique increasingly used in elderly patients with aortic stenosis. Their flagship product captures and filters embolic debris (clots, calcium fragments, valve tissue) released into the bloodstream during the procedure before it can reach the brain and cause stroke. The company progressed through the EU's SME Instrument pathway, moving from feasibility validation (SME-1) to full commercial development (SME-2), indicating a product-stage company preparing for regulatory approval and market entry rather than early-stage research.
Both projects — 'Filterlex' (2018) and 'CAPTIS' (2019) — are focused exclusively on EPD technology for TAVI procedures, with CAPTIS receiving EUR 2.135M to develop it to market readiness.
Project keywords across both grants consistently center on TAVI, aortic stenosis, heart valve replacement, and stroke prevention in elderly patients.
The SME-1 → SME-2 progression demonstrates execution of a structured EU commercialization pathway, implying internal capability in prototype development, clinical evidence gathering, and market access planning.
The CAPTIS project description — 'embolic protection device for stroke prevention during heart valve replacement' — implies expertise in catheter-based device mechanics and intra-cardiac filtration engineering.
Filterlex Medical's two-project H2020 track covers 2018–2021, a compact window that nonetheless tells a clear story of product maturation rather than research diversification. The first project ('Filterlex', SME-1) in 2018 established the core concept — a full-body EPD for TAVI — and was funded at the feasibility level of EUR 50,000. The second project ('CAPTIS', SME-2) in 2019 scaled to EUR 2.135M, shifting focus from concept validation to building the clinical and commercial case for market entry. No keyword drift is visible between early and recent phases, which is consistent with a single-product company executing a linear development roadmap rather than exploring new research directions.
Filterlex is on a direct product commercialization trajectory — if CAPTIS completed successfully, they would be seeking CE marking, clinical partnerships, and hospital procurement agreements in European cardiovascular centers, not new R&D cycles.
Filterlex has operated exclusively as a solo coordinator through the SME Instrument (now EIC Accelerator) scheme, which is by design — these grants are for individual companies proving a product, not building research networks. They have zero recorded consortium partners across both projects, so there is no collaboration history to analyze. A potential partner should expect to engage them as a technology provider or clinical collaborator rather than as an experienced consortium co-builder.
Filterlex has no recorded EU consortium partners — both projects were awarded under the SME Instrument, which funds companies individually without multi-partner consortia. Their collaboration footprint within H2020 is effectively zero beyond their own organization.
Filterlex occupies a highly specific niche: stroke prevention specifically for TAVI, one of the fastest-growing cardiac procedures globally due to aging populations and the shift away from open-heart surgery. While several EPD products exist for TAVI (e.g., Claret Sentinel), Filterlex's 'full-body' protection claim suggests a differentiated design approach targeting broader cerebral coverage than competitors. As an Israeli SME accessing EU funding and presumably targeting European CE-marked markets, they sit at the intersection of Israeli medtech innovation and European cardiovascular adoption.
